What are the treatment options for paroxysmal extreme pain disorder? (Q38997463)

8 September 2017

What are the treatment options for paroxysmal extreme pain disorder? (English)

1 reference

8 September 2017

Marc R Suter

1

1 reference

8 September 2017

10 June 2015

1 reference

8 September 2017

1 reference

8 September 2017

5

1 reference

8 September 2017

229-232

1 reference

8 September 2017

4

1 reference

The Na(V)1.7 sodium channel: from molecule to man.

8 September 2017

1 reference

SCN9A mutations in paroxysmal extreme pain disorder: allelic variants underlie distinct channel defects and phenotypes

21 January 2018

1 reference

Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable

21 January 2018

1 reference

p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation inducing a cold sensitive paroxysmal extreme pain disorder.

21 January 2018

1 reference

Paroxysmal extreme pain disorder (previously familial rectal pain syndrome)

21 January 2018

1 reference

NaV1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders.

21 January 2018

1 reference

Short-lasting unilateral neuralgiform headache attacks with ispilateral facial flushing is a new variant of paroxysmal extreme pain disorder

21 January 2018

1 reference

Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use.

21 January 2018

1 reference

Deconstructing the neuropathic pain phenotype to reveal neural mechanisms

21 January 2018

1 reference

A single sodium channel mutation produces hyper- or hypoexcitability in different types of neurons

21 January 2018

1 reference

ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors.

21 January 2018

1 reference

The effect of treatment history on therapeutic outcome: psychological and neurobiological underpinnings

21 January 2018

1 reference

Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis

21 January 2018

1 reference

Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society.

21 January 2018

1 reference

Paroxysmal extreme pain disorder: a molecular lesion of peripheral neurons

21 January 2018

1 reference

Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.

21 January 2018

1 reference

Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state

21 January 2018

1 reference

A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia

21 January 2018

1 reference

Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PMT.15.24

1 reference

8 September 2017

1 reference

PubMed ID

26059255